{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 76 of 92', 'CR845-CLIN3102', '10.0', 'Ethics and Regulatory Compliance', '10.1', 'Independent Ethics Committee or Institutional Review Board', 'A properly constituted, valid IRB or Independent Ethics Committee must review and', \"approve the protocol, the Investigator's Brochure, ICF, and related patient information\", 'and recruitment materials (if applicable) before the start of the study. It is the', 'responsibility of the Investigator to ensure that written informed consent is obtained from', 'the patient before any activity or procedure is undertaken that is not part of routine care.', 'The IRB will review all appropriate study documentation in order to safeguard the rights,', 'safety, and well-being of the patients. The study will only be conducted at a site where', 'IRB approval has been obtained. The protocol, IB, ICF, advertisements (if applicable),', 'written information given to the patients, safety updates, annual progress reports, and any', 'revisions to these documents will be provided to the IRB by the Investigator.', 'If it is necessary to amend the protocol and/or ICF during the course of the study, the', 'Investigator must ensure that the IRB reviews and approves these amended documents.', 'Except for changes necessary to eliminate an immediate hazard to study patients, or when', 'the change involves only logistical or administrative aspects of the study (eg, change in', 'monitor, change of telephone number), no amendments to the study protocol will be', 'made without the prior written agreement of the Sponsor and acknowledgement by the', 'Investigator and, as applicable, the IRB.', 'The Investigator(s) will maintain documentation of the composition of the IRB as well as', 'all correspondence with the IRB. The Investigator(s) will comply with local', 'requirements for routine reporting to the IRB as well as local and government', 'requirements for notifying the IRB of SAEs. The Investigator will provide Cara', 'Therapeutics or its designee copies of all IRB approval notices, correspondence, annual', 'reports, and final study progress reports.', '10.2', 'Ethical Conduct of the Study', 'The study will be conducted in accordance with ethical principles founded in the', 'Declaration of Helsinki and all accepted amendments, the ICH principles of GCP', '(including archiving of essential study documents) and the applicable regulations of the', 'country in which the study is conducted.', 'The Investigator will be thoroughly familiar with the appropriate use of the study drug as', \"described in the protocol, Investigator's Brochure, and any other study-related manual(s)\", 'Essential clinical documents will be maintained to demonstrate the validity of the study', 'and the integrity of the data collected. A study master file must be established for the', 'study, and retained according to the appropriate regulations.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 78 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 77 of 92', 'CR845-CLIN3102', '10.3', 'Informed Consent Process', 'Informed consent is required for all patients participating in this study. In obtaining and', 'documenting informed consent, the Investigator must comply with applicable regulatory', 'requirements and must adhere to GCP regulations. It is the responsibility of the', 'Investigator to ensure that written informed consent is obtained from the patient before', 'any activity or procedure is undertaken that is not part of routine care.', \"Informed consent is a process that is initiated prior to the individual's agreeing to\", \"participate in the study and that continues throughout the individual's study participation.\", 'The Investigator or designee will discuss extensively with the participant patient the', 'study risks. Copies of the current, IRB-approved ICF detailing the risks and benefits of', 'study participation will be provided to the participants. Consent forms describing in', 'detail the study drug and study procedures/intervention and risks will be fully explained', 'to the patient and written documentation of informed consent will be required prior to', 'starting participation in the study. Upon reviewing the document, the Investigator or', 'designee will explain the research study to the participant and answer any questions that', 'may arise. The participants will sign the ICF prior to any procedures being done', 'specifically for the study. The participants should have sufficient opportunity to discuss', 'the study and process the information in the consent process prior to agreeing to', 'participate. The participants may withdraw consent at any time throughout the course of', 'the study. A signed copy of the ICF will be given to the participants for their records.', 'Patients must sign a separate informed consent prior to participating in the Open-label', 'Treatment Period.', '10.4', 'Patient Confidentiality', 'In order to maintain patient privacy, all eCRFs, study drug accountability records, study', 'reports, and communications will identify the patient by assigned patient number. The', 'Investigator will grant monitor(s) and auditor(s) from the Sponsor or its designee and', \"regulatory authority(ies) access to the patient's original medical records for verification\", \"of data gathered on the eCRFs and to audit the data collection process. The patient's\", 'confidentiality will be maintained and will not be made publicly available to the extent', 'permitted by the applicable laws and regulations.', 'Participant confidentiality is strictly held in trust by the participating Investigators, their', 'staff, and the Sponsor(s) and their agents. This confidentiality is extended to cover', 'testing of biological samples and genetic tests in addition to the clinical information', 'relating to participating patients.', 'The study protocol, documentation, data, and all other information generated will be held', 'in strict confidence. No information concerning the study or the data will be released to', 'any unauthorized third party without prior written approval of the Sponsor.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 79 of 95']\n\n###\n\n", "completion": "END"}